Open Site Navigation

Barriers of Current Treatment Options for Acute Muscle Spasm of the Back 

Neurana conducted qualitative and quantitative prescriber research survey of an aggregate of over 245 prescribers that commonly treat muscle spasms

Cause Drowsiness

Impact on Cognitive Function

Patient Dislike of Sedative Impact

Compare the Target Adverse Event Profile of OMZYA® to Other Approved Muscle Relaxants

Cyclobenzaprine

Flexeril®

Drowsiness

Dry mouth, fatigue, headache 

PATIENT INFORMATION

May impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle

Drowsiness 

Metaxalone

Skelaxin®

Dizziness, headache, nervousness or “irritability”

Digestive: nausea, vomiting, gastrointestinal upset
Immune System: hypersensitivity reaction, rash with or without pruritus Hematologic: leukopenia; hemolytic anemia

Hepatobiliary: jaundice

PATIENT INFORMATION

May impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle

Drowsiness 

Carisoprodol

Soma®

Dizziness, headache

WARNINGS & PRECAUTIONS

Due to sedative properties,
may impair ability to perform hazardous tasks such as driving or operating machinery

Based on completed Phase 1 and Phase 2 studies of OMZYA®

The ONLY

potential non-opioid,

non-drowsy,

non-CNS impairing muscle relaxant 

Model_Backpain_lo.jpg

20 Million 

US adults are treated annually for acute muscle spasms 

Sustained involuntary contractions of a muscle or muscle group that cannot relax

Debilitating medical condition usually localized within the spinal structure

Current products do not meet patient needs

Sustained involuntary contractions of a muscle or muscle group that cannot relax

Debilitating medical condition usually localized within the spinal structure

Current products do not meet patient needs

“I would use a product like OMZYA® a lot more than other muscle relaxants because of the side effect profile: this would be first line instead of Flexeril … I think over time such a product could replace Flexeril as patients wouldn’t be so sleepy.”

      Primary Care Provider

Neurana conducted qualitative and quantitative prescriber research survey of an aggregate of over 245 prescribers that commonly treat muscle spasms